JP2009517417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009517417A5 JP2009517417A5 JP2008542640A JP2008542640A JP2009517417A5 JP 2009517417 A5 JP2009517417 A5 JP 2009517417A5 JP 2008542640 A JP2008542640 A JP 2008542640A JP 2008542640 A JP2008542640 A JP 2008542640A JP 2009517417 A5 JP2009517417 A5 JP 2009517417A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- ring
- nhco
- nhso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000753 cycloalkyl group Chemical group 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000001246 bromo group Chemical group Br* 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000028004 allergic respiratory disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000002491 encephalomyelitis Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- -1 trifluoromethoxy, trifluoromethyl methylthio Chemical group 0.000 claims 2
- CLIVJKSOVQCFOU-UHFFFAOYSA-N 2-[4-bromo-2-[3-(1-phenylcyclopropyl)-1,2,4-oxadiazol-5-yl]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(Br)C=C1C1=NC(C2(CC2)C=2C=CC=CC=2)=NO1 CLIVJKSOVQCFOU-UHFFFAOYSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000035939 Alveolitis allergic Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000027445 Farmer Lung Diseases 0.000 claims 1
- 206010016228 Fasciitis Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 206010065673 Nephritic syndrome Diseases 0.000 claims 1
- 206010031264 Osteonecrosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010069714 Ross syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000016247 Soft tissue disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 208000025434 cerebellar degeneration Diseases 0.000 claims 1
- 208000013116 chronic cough Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 125000002720 diazolyl group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000022195 farmer lung disease Diseases 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 208000016366 nasal cavity polyp Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0524428.0A GB0524428D0 (en) | 2005-11-30 | 2005-11-30 | Medicinal use of receptor ligands |
| PCT/EP2006/011216 WO2007062773A1 (en) | 2005-11-30 | 2006-11-22 | Oxadiazole derivatives with crth2 receptor activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009517417A JP2009517417A (ja) | 2009-04-30 |
| JP2009517417A5 true JP2009517417A5 (https=) | 2010-01-14 |
Family
ID=35685792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542640A Withdrawn JP2009517417A (ja) | 2005-11-30 | 2006-11-22 | Ｃｒｔｈ２レセプター活性を有するオキサジアゾール誘導体類 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080312220A1 (https=) |
| EP (1) | EP1960376A1 (https=) |
| JP (1) | JP2009517417A (https=) |
| KR (1) | KR20080072688A (https=) |
| CN (1) | CN101316829A (https=) |
| AU (1) | AU2006319462A1 (https=) |
| BR (1) | BRPI0619260A2 (https=) |
| CA (1) | CA2631652A1 (https=) |
| CR (1) | CR10034A (https=) |
| EA (1) | EA200801494A1 (https=) |
| EC (1) | ECSP088479A (https=) |
| GB (1) | GB0524428D0 (https=) |
| HN (1) | HN2008000817A (https=) |
| NO (1) | NO20082917L (https=) |
| SV (1) | SV2009002925A (https=) |
| WO (1) | WO2007062773A1 (https=) |
| ZA (1) | ZA200804687B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2229358E (pt) | 2007-12-14 | 2011-06-29 | Pulmagen Therapeutics Asthma Ltd | Indoles e sua utilização terapêutica |
| US8273769B2 (en) | 2009-02-12 | 2012-09-25 | Merck Serono Sa | Phenoxy acetic acid derivatives |
| JP5069804B2 (ja) * | 2010-03-01 | 2012-11-07 | 隆雄 篠澤 | 筋萎縮性側索硬化症（ａｌｓ）の患者の進行度を判定し進行のモニターを行う方法 |
| EP2590944B1 (en) | 2010-07-05 | 2015-09-30 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| EP2790696A1 (en) | 2011-12-16 | 2014-10-22 | Atopix Therapeutics Limited | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| JP6097765B2 (ja) | 2011-12-21 | 2017-03-15 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用 |
| WO2014006585A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| CN104744429B (zh) * | 2013-12-27 | 2016-09-28 | 启东韶远化学科技有限公司 | 一种环并[b]噻吩-3(2H)-酮-1,1-二氧化物的简单合成方法 |
| DK3307262T3 (da) * | 2015-06-15 | 2021-08-09 | Nmd Pharma As | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser |
| WO2018170067A1 (en) * | 2017-03-14 | 2018-09-20 | Dana-Farber Cancer Institute, Inc. | Small molecule sensitization of bax activation for induction of cell death |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| TWI780281B (zh) * | 2017-12-14 | 2022-10-11 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| MX2021013507A (es) * | 2019-06-19 | 2021-12-10 | Nmd Pharma As | Proceso para la preparacion de inhibidores del canal de cloruro ciec-1. |
| WO2020254559A1 (en) | 2019-06-19 | 2020-12-24 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| EP2423190A1 (en) | 2002-05-16 | 2012-02-29 | Shionogi&Co., Ltd. | Compounds Exhibiting PGD 2 Receptor Antagonism |
| AU2003231513A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Pgd2 receptor antagonist |
| GB2388540A (en) | 2002-05-17 | 2003-11-19 | Bayer Ag | New use of Ramatroban |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| BRPI0511676A (pt) * | 2004-05-29 | 2008-01-08 | 7Tm Pharma As | uso medicinal de ligandos receptores |
-
2005
- 2005-11-30 GB GBGB0524428.0A patent/GB0524428D0/en not_active Ceased
-
2006
- 2006-11-22 KR KR1020087012911A patent/KR20080072688A/ko not_active Ceased
- 2006-11-22 WO PCT/EP2006/011216 patent/WO2007062773A1/en not_active Ceased
- 2006-11-22 AU AU2006319462A patent/AU2006319462A1/en not_active Abandoned
- 2006-11-22 EA EA200801494A patent/EA200801494A1/ru unknown
- 2006-11-22 CA CA002631652A patent/CA2631652A1/en not_active Abandoned
- 2006-11-22 US US12/094,907 patent/US20080312220A1/en not_active Abandoned
- 2006-11-22 EP EP06829107A patent/EP1960376A1/en not_active Withdrawn
- 2006-11-22 BR BRPI0619260-2A patent/BRPI0619260A2/pt not_active IP Right Cessation
- 2006-11-22 CN CNA2006800441506A patent/CN101316829A/zh active Pending
- 2006-11-22 JP JP2008542640A patent/JP2009517417A/ja not_active Withdrawn
-
2008
- 2008-05-29 EC EC2008008479A patent/ECSP088479A/es unknown
- 2008-05-29 ZA ZA200804687A patent/ZA200804687B/xx unknown
- 2008-05-30 CR CR10034A patent/CR10034A/es not_active Application Discontinuation
- 2008-05-30 SV SV2008002925A patent/SV2009002925A/es not_active Application Discontinuation
- 2008-06-02 HN HN2008000817A patent/HN2008000817A/es unknown
- 2008-06-27 NO NO20082917A patent/NO20082917L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009517417A5 (https=) | ||
| JP2008500991A5 (https=) | ||
| JP2010509342A5 (https=) | ||
| JP6017313B2 (ja) | 化合物および方法 | |
| CA2797663A1 (en) | Compounds that modulate intracellular calcium | |
| JP2015502387A5 (https=) | ||
| US8017631B2 (en) | Oxadiazole derivatives and their medical use | |
| JP2020537657A5 (https=) | ||
| JP2010519206A5 (https=) | ||
| JP2007500715A5 (https=) | ||
| JP2006514946A5 (https=) | ||
| JP2016518399A5 (https=) | ||
| JP2008526717A5 (https=) | ||
| HRP20140098T1 (hr) | Derivati piridin-4-ila kao agonisti s1p1/edg1 | |
| RU99112569A (ru) | Бициклические арильные карбоксамиды и их терапевтическое применение | |
| JP2006513268A5 (ja) | アンタゴニスト活性を有するベンゾアゾリルピペラジン誘導体 | |
| ZA200609277B (en) | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | |
| JP2017512779A5 (https=) | ||
| JP2013540712A5 (https=) | ||
| JP2008516968A5 (https=) | ||
| KR20110067034A (ko) | 신규의 2-아미도티아디아졸 유도체 | |
| CA2533509A1 (en) | Piperidine compounds and pharmaceutical compositions containing them | |
| JP2016532669A5 (https=) | ||
| JP2019501927A5 (https=) | ||
| JP2007532637A5 (https=) |